Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) shares fell 3.9% on Monday . The company traded as low as $13.44 and last traded at $13.44. 3,559 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 3,047 shares. The stock had previously closed at $13.98.
Finch Therapeutics Group Price Performance
The stock’s 50-day simple moving average is $13.32 and its two-hundred day simple moving average is $12.95. The firm has a market capitalization of $21.64 million, a P/E ratio of -1.52 and a beta of 1.17.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Recommended Stories
- Five stocks we like better than Finch Therapeutics Group
- What Are Dividend Challengers?
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Dell and HP Are Raising Prices—And Investors Should Take Note
- Conference Calls and Individual Investors
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
